Introduction {#sec1-1}
============

Cherry angiomas (CAs) or "Campbell de Morgan spots" are one of the most common benign cutaneous vascular lesions. They present as asymptomatic, small, bright-red papules usually on the trunk and extremities of older individuals.\[[@ref1]\] The frequency of CAs increases with age, but have no reported clinical consequences.\[[@ref2]\] The incidence of CAs was 49.5% in males, who seem to be more commonly affected than females.\[[@ref3]\] The treatment of CAs is cosmetic because they are benign and asymptomatic.\[[@ref1]\]

The pathogenesis of CAs is not entirely known. Reduced expression of miR-424 in CAs was found to be associated with abnormal angiogenesis through MEK1 or cyclin E1.\[[@ref4]\] Human herpesvirus 8 has a possible role in eruptive CAs.\[[@ref5]\] Some somatic genetic mutations have been identified in CAs.\[[@ref6]\]

Risk factors associated with the development of multiple CAs could include age, chronic immunosuppression, chronic graft-versus-host disease, and malignancy.\[[@ref7][@ref8]\] Some studies suggest an association between CAs and the exposure to certain chemicals and drugs such as cyclosporine,\[[@ref9]\] sulfur mustard,\[[@ref10]\] nitrogen mustard,\[[@ref11]\] and bromides.\[[@ref12]\]

Studies on risk factors associated with CAs are few and limited mainly to case reports and uncontrolled studies. Controlled studies, which explored a limited number of variables, are surprisingly very few for this common condition. This study was done to explore risk factors associated with the occurrence of CAs.

Materials and Methods {#sec1-2}
=====================

This was a case--control study conducted at King Abdulaziz Medical City, one of the largest tertiary care centers in Riyadh, Saudi Arabia. Ethical approval was obtained from the Institutional Review Board of King Abdullah International Medical Research Center and informed written consent was obtained from all participants.

Cases were defined as patients with five or more CAs. Controls were age- and gender-matched patients who did not have any CAs. Only Saudi patients aged ≥18 years and admitted to the hospital were included in the study. Patients who refused a full body examination, or had received previous treatment for CAs, or had 1--4 CAs were excluded from the study.

The target case-to-control ratio was 1:2. The sample size was estimated as hundred cases and two hundred controls using OpenEpi sample size calculator. The calculation was based on an estimated 30%--40% exposure to the risk factor in the control group, to detect an odds ratio (OR) of 2.0 or more at the 95% confidence level and power of 80%. A nonprobability consecutive sampling was used to select the cases, while the selection of controls was based on matching for age and gender.

Full-body skin examination was performed on all patients. Variables consisted of demographics, Fitzpatrick skin phototype, and region of residence. Furthermore, the duration of CA, body site, and diameter were documented. Data regarding family history, medical conditions, malignancies, and environmental triggers were collected. Details of current medications were gathered from the electronic medical record.

Statistical analysis was done using Statistical package for the Social Sciences (SPSS) version 24 (SPSS Inc., Chicago, IL, USA). Categorical variables were presented as frequencies and percentages and were compared using the Chi-square test. Numerical variables were reported as means with standard deviation and were compared by Student\'s *t*-test. Skewed numerical data were presented as median and inter-quartile range. Step-wise multivariate logistic regression analysis was performed to determine any associated risk factors, if any, for the development of CAs. Variables entered in the model were those with *P* \< 0.2 between cases and controls in the bivariate analysis. The results of regression analysis were presented as OR with 95% confidence interval. For all the statistical tests, *P* \< 0.05 was considered statistically significant.

Results {#sec1-3}
=======

A total of hundred cases and two hundred controls were enrolled in the study. The most common site of CAs was the trunk (mainly the chest) followed by the proximal extremities, head and neck, distal extremities, hands, and feet \[[Figure 1](#F1){ref-type="fig"}\]. Similarly, the trunk had the highest number and CAs with the largest diameter \[[Table 1](#T1){ref-type="table"}\].
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###### 

Characteristics of cherry angiomas based on body site (*n*=100)

  Body site                                         
  --------------------- ------------- ------------- -----------
  Head and neck         1.86 (1.21)   0.6 (0.3)     1.8 (1.1)
  Chest and axillae     3.61 (2.67)   0.7 (0.5)     1.9 (1.3)
  Abdomen               3 (2.0)       1 (0.3)       2.3 (2.1)
  Back                  3.73 (2.87)   0.74 (0.56)   1.9 (1.3)
  Arms                  3 (2.0)       0.6 (0.3)     1.3 (0.8)
  Forearms              2 (1.0)       0.8 (0.6)     1.5 (0.8)
  Hands                 1 (0)         0.9 (0.7)     0.9 (0.7)
  Thighs and buttocks   2.29 (1.29)   0.7 (0.3)     2 (1.0)
  Legs                  2 (1.0)       0.7 (0.4)     1 (0.5)
  Feet\*                2 (0)         1 (0)         1 (0)

\*Only one patient had cherry angioma on the foot. SD=Standard deviation

Patient characteristics are summarized in [Table 2](#T2){ref-type="table"}. No statistically significant difference was found between cases and controls with regard to age and gender. Similarly, no difference was found in body mass index, region of residence, job, and history of smoking. A family history of CA was positive in 12% of cases. The median duration of CAs was 6 years (interquartile range 3--20).

###### 

Bivariate analysis of patient characteristics

  Characteristic                                         Control (*n*=200)    Cases (*n*=100)         *P-Value*                 
  ------------------------------------------------------ -------------------- ----------------------- ------------ ------------ -------
  Age (years)                                            200                  54.0±19.0               100          57.0±19.0    0.155
  BMI                                                    200                  28.89±8.98              100          28.26±8.10   0.540
  Characteristics                                        Cases (n=100)N (%)   Controls (n=200)N (%)   *P -Value*                
  Gender                                                                                                                        
   Male                                                  100 (50.0)           51 (51.0)               0.870                     
   Female                                                100 (50.0)           49 (49.0)                                         
  Region of residence                                                                                                           
   Central                                               158 (79.0)           82 (82.0)               0.949                     
   North                                                 12 (6.0)             6 (6.0)                                           
   South                                                 8 (4.0)              4 (4.0)                                           
   East                                                  12 (6.0)             4 (4.0)                                           
   West                                                  10 (5.0)             4 (4.0)                                           
  Job                                                                                                                           
   Physician                                             0 (0)                1 (1.0)                 0.330                     
   Teacher                                               4 (2.0)              5 (5.0)                                           
   Military                                              20 (10.0)            7 (7.0)                                           
   Homemaker                                             88 (44.0)            43 (43.0)                                         
   Retired                                               58 (29.0)            35 (35.0)                                         
   Governmental                                          4 (2.0)              3 (3.0)                                           
   Student                                               9 (4.5)              3 (3.0)                                           
   None                                                  5 (2.5)              1 (1.0)                                           
   Other                                                 12 (6.0)             2 (2.0)                                           
  Smoker                                                                                                                        
   No                                                    176 (88.0)           92 (92.0)               0.290                     
   Yes                                                   24 (12.0)            8 (8.0)                                           
  Family history\*                                       \-                   12 (12.0)                                         
  Duration of cherry angiomas in years\*, median (IQR)   \-                   6 (3-20)                                          

\*Cases only. BMI=Body mass index, SD=Standard deviation, IQR=Interquartile range

Bivariate analysis identified benign prostatic hyperplasia (OR = 2.591), malignancy (OR = 2.567), tamsulosin (OR = 3.171), and clopidogrel (OR = 0.321) as statistically significant associations \[[Table 3](#T3){ref-type="table"}\]. After multivariate logistic regression analysis, only tamsulosin and clopidogrel were found to be independent risk factors for CAs \[[Table 4](#T4){ref-type="table"}\]. Patients on tamsulosin were more likely to have CAs (OR = 3.475, *P* = 0.009), while those on clopidogrel seem to be less likely to have CAs (OR = 0.281, *P* = 0.028). Malignancy tended to have more association with CAs, but this was not statistically significant (*P* = 0.07).

###### 

Bivariate analysis: Factors associated with cherry angioma

                                     Controls (n=200)N (%)   Cases (n=100)N (%)   Crude OR   *P -Value*   aOR     *P -Value*   95% CI for aOR
  ---------------------------------- ----------------------- -------------------- ---------- ------------ ------- ------------ ----------------
  Diabetes                           86 (43.0)               47 (47.0)            1.176      0.511        0.925   0.806        0.496-1.726
  Hypertension                       94 (47)                 55 (55.0)            1.378      0.192        1.388   0.312        0.734-2.625
  Dyslipidemia                       36 (18.0)               18 (18.0)            1.000      1.0          0.980   0.956        0.476-2.018
  Coronary artery disease            16 (8.0)                8 (8.0)              1.000      1.0          0.793   0.674        0.270-2.332
  Stroke                             13 (6.5)                8 (8.0)              1.251      0.632        1.544   0.413        0.546-4.367
  Rheumatoid arthritis               3 (1.5)                 4 (4.0)              2.736      0.193        4.802   0.133        0.620-37.192
  Asthma                             13 (6.5)                5 (5.0)              0.757      0.607        0.572   0.382        0.163-2.002
  Hypothyroidism                     12 (6.0)                7 (7.0)              1.179      0.737        1.020   0.970        0.362-2.878
  Hyperthyroidism                    1 (0.5)                 2 (2.0)              4.061      0.255        3.791   0.349        0.233-61.716
  Chronic kidney disease             14 (7.0)                8 (8.0)              1.155      0.754        0.929   0.890        0.328-2.635
  Cirrhosis                          2 (1.0)                 2 (2.0)              2.020      0.485        1.174   0.896        0.107-12.916
  Benign prostatic hyperplasia       10 (5.0)                12 (12.0)            2.591      0.033        0.333   0.402        0.025-4.363
  Previous or current malignancies   11 (5.5)                13 (13.0)            2.567      0.028        3.419   0.019        1.219-9.590
  Previous chemotherapy              4 (2.0)                 1 (1.0)              0.495      0.632        0.192   0.234        0.013-2.905
  Previous immunosuppression         16 (8.0)                10 (10.0)            1.278      0.562        0.509   0.385        0.111-2.338
  Previous organ transplant          4 (2.0)                 5 (5.0)              2.579      0.165        5.357   0.110        0.684-41.939
  Tamsulosin                         9 (4.5)                 13 (13.0)            3.171      0.011        9.613   0.086        0.729-126.809
  Clopidogrel                        23 (11.5)               4 (4.0)              0.321      0.041        0.244   0.021        0.074-0.812
  Fitzpatrick skin type                                                                                                        
   II and III                        78 (39.0)               36 (36.0)            1.038      0.848        0.975   0.907        0.640-1.487
   IV                                111 (55.5)              60 (60.0)                                                         
   V and VI                          11 (5.5)                4 (4.0)                                                           
  Pregnancy                          14 (7.0)                3 (3.0)              0.411      0.170        0.442   0.240        0.114-1.723

CI=Confidence interval, OR=Odds ratio, aOR=Adjusted OR

###### 

Multivariate logistic regression analysis: Factors associated with cherry angioma

                                     SE      OR      95% CI   *P -Value*   
  ---------------------------------- ------- ------- -------- ------------ -------
  Previous or current malignancies   0.443   2.232   0.936    5.323        0.07
  Tamsulosin                         0.480   3.475   1.357    8.899        0.009
  Clopidogrel                        0.576   0.281   0.091    0.870        0.028
  Constant                           0.139   0.462                         0.000

CI=Confidence interval, OR=Odds ratio, SE=Standard error

Discussion {#sec1-4}
==========

Studies on CAs are generally limited. Trunk was the most common site affected with CAs in our cases, which is in agreement with the literature and clinical observation.\[[@ref1]\] The pathogenesis of CAs is still poorly understood. Genetic factors could play a role in the development of CAs. Family history of CAs was found in 12% of our cases. Somatic mutations in GNAQ and GNA11 genes were recently identified in CAs.\[[@ref6]\] These genes are also known to be involved in the pathogenesis of other cutaneous vascular conditions such as capillary malformations.

Controlled studies on the risk factors of CAs are scarce. Borghi *et al*. assessed the risk factors of eruptive CAs in a total of 1032 patients.\[[@ref13]\] Those with eruptive CAs had ≥30 CAs. The comparative group had either no or \<30 CAs. Age, immunosuppressive therapy, and malignancy were identified as independent risk factors for eruptive CAs. Malignancy in our study had a tendency of having statistically significant association with CAs., The number of CAs was significantly more on the skin of the affected breast in patients with unilateral breast cancer.\[[@ref14]\] Serum lipids were shown to be more elevated in patients with CAs in a case--control study.\[[@ref15]\] The lipid profile was not assessed in our study.

Tamsulosin and clopidogrel were identified in our study as independently significant associations with CAs. To the best of our knowledge, this association has not been previously reported. We found that patients on tamsulosin were more likely to have CAs. Tamsulosin is a selective alpha1A and alpha1D-adrenergic receptor blocker that is used in the treatment of BPH.\[[@ref16]\] Alpha-1 adrenergic receptors are mainly found in the prostate and bladder. Tamsulosin works by relaxing smooth muscles in the prostate and bladder and therefore, improves urinary symptoms in patients with BPH. Although tamsulosin primarily works on the lower urinary tract, it has been shown to have some effect on the blood vessels, leading to vasodilation.\[[@ref17]\] This might explain the association between tamsulosin and CAs found in our study.

Our findings indicate that clopidogrel seems to have a protective role against CA formation. Clopidogrel is an antiplatelet that prevents platelet aggregation through the inhibition of adenosine diphosphate.\[[@ref18]\] It is used for the prevention of coronary artery disease and stroke. Clopidogrel has been recently shown to have an anti-angiogenic effect.\[[@ref19]\] Both the number of microvessels and expression of vascular endothelial growth factor were significantly reduced by clopidogrel.

Our study has some limitations. *Post hoc* analysis showed the power of study as 60.45%, which could be due to the small sample size. The study was done at one center and therefore, its findings cannot be generalized. Another limitation is that our study design depended to some extent on patient recall of information. A better design would have been a prospective cohort but that would have been time-consuming and expensive.

Conclusion {#sec1-5}
==========

We identified tamsulosin as a possible risk factor for the development of CAs. However, clopidogrel seems to have a protective role, possibly preventing the development of CAs. Future well-designed studies are needed to confirm these findings.
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